Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 16/20 | 0.56 |
| ▸ | IKBKB | O14920 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12922023 | 0.99 | CHEK1 (0.57) | CHEK1IKBKBMEN1TSHRHTT | |
| SCHEMBL12922027 | 0.91 | CHEK1 (0.46) | CHEK1 | |
| SCHEMBL8847235 | 0.90 | CHEK1 (0.59) | CHEK1IKBKB | |
| SCHEMBL14997873 | 0.90 | CHEK1 (0.52) | CHEK1IKBKB | |
| SCHEMBL29900119 | 0.89 | CHEK1 (0.52) | CHEK1IKBKB | |
| SCHEMBL4343193 | 0.89 | CHEK1 (0.52) | CHEK1IKBKB | |
| Hydrochloric Acid SCHEMBL27747350 | 0.89 | CHEK1 (0.58) | CHEK1IKBKB | |
| SCHEMBL12948547 | 0.89 | CHEK1 (0.51) | CHEK1IKBKBMCHR1 | |
| SCHEMBL29900120 | 0.89 | CHEK1 (0.68) | CHEK1 | |
| SCHEMBL29900038 | 0.89 | CHEK1 (0.68) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249154-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-02-02 | — | — | US | disclosed |
| US-8962626-B2 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2015-02-24 | — | — | US | disclosed |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2013-06-06 | — | — | US | disclosed |
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | WU, ZHANGGUI (CN) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | CYP3A5, ABCC5, DPYD | CHEK1 2344/4885IKBKB 2148/4885MEN1 1290/4885 |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, PLK1 | CHEK1 2/4885IKBKB 704/4885MEN1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.